US Pat. No. 9,439,959

CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES

TAKEDA VACCINES, INC., B...

1. A chimeric influenza virus-like particle (VLP) comprising a gag poiypeptide, an influenza hemagglutinin polypeptide, and
an influenza neuraminidase polypeptide, wherein said VIP does not comprise influenza matrix M1 protein or fragments thereof;
and wherein the hemagglutinin polypeptide subtype is selected from the group consisting of H1, H3, and H5.
US Pat. No. 9,272,028

NOROVIRUS VACCINE FORMULATIONS

TAKEDA VACCINES, INC., B...

1. A composition comprising a first monovalent virus like particle (VLP) derived from a genogroup I Norovirus and a second
monovalent VLP derived from a genogroup II Norovirus and at least one adjuvant, wherein the adjuvant is monophosphoryl lipid
A (MPL) and/or an aluminum salt, and wherein the composition is formulated as a liquid.
US Pat. No. 9,783,579

COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES

Takeda Vaccines, Inc., D...

1. A dengue-2 virus polypeptide comprising SEQ ID NO: 10.
US Pat. No. 9,408,901

COMPOSITIONS, METHODS AND USES FOR DENGUE VIRUS SEROTYPE-4 CONSTRUCTS

TAKEDA VACCINES, INC, De...

1. A nucleic acid molecule comprising a chimeric flavivirus construct comprising nucleic acid sequences encoding nonstructural
proteins and one or more structural proteins from a live, attenuated dengue-2 virus and at least encoding one or more structural
proteins from a second dengue virus, the second flavivirus is selected from the group dengue-1, dengue-3 or dengue-4 virus
wherein the chimeric construct further comprises one or more mutations comprising, a mutation in an envelope (E) protein at
an amino acid position synonymous of dengue 4 to amino acid 417 when the E protein is from the second flavivirus wherein the
mutation in the envelope (E) protein at the position synonymous to amino acid 417 changes glutamic acid to a positively charged
residue; a mutation in the capsid protein at an amino acid position synonymous to amino acid 107 in the attenuated dengue-2
wherein the mutation in the capsid (C) protein at the position synonymous to amino acid 107 changes cysteine to an aromatic
amino acid residue in the attenuated dengue-2, and a mutation in NS4A at an amino acid position synonymous to amino acid position
17 in the attenuated dengue-2.
US Pat. No. 9,518,096

VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY

TAKEDA VACCINES, INC., B...

1. An isolated polypeptide or fragment thereof having a composite amino acid sequence, wherein said composite amino acid sequence
comprises SEQ ID NO: 1 or SEQ ID NO: 22.
US Pat. No. 9,801,934

PARENTERAL NOROVIRUS VACCINE FORMULATIONS

TAKEDA VACCINES, INC., C...

1. A buffered composition comprising a first monovalent VLP derived from a first Norovirus genogroup and a second monovalent
VLP derived from a second Norovirus genogroup, wherein the first Norovirus genogroup is genogroup I and the second Norovirus
genogroup is genogroup II, wherein said buffer is selected from L-histidine and imidazole, and wherein the composition is
formulated as a liquid.
US Pat. No. 9,308,249

NOROVIRUS VACCINE FORMULATIONS

TAKEDA VACCINES, INC., B...

1. An immunogenic composition comprising at least one Norovirus antigen and an effective amount of at least one adjuvant,
wherein the adjuvant is a toll-like receptor (TLR) agonist that is not a bacterial exotoxin, wherein said antigen comprises
Norovirus virus-like particles (VLPs), and wherein the composition is formulated as a stable dry powder, wherein the percent
aggregation of VLPs in the composition remains constant or decreases when measured over a twelve month period.
US Pat. No. 9,359,410

VIRUS LIKE PARTICLE PURIFICATION

TAKEDA VACCINES INC., Bo...

1. A method of purifying Calicivirus virus-like particles (VLPs) comprising contacting a solution containing said VLPs with
at least one chromatographic material, wherein the at least one chromatographic material is an ion exchange chromatographic
material, wherein the chromatographic materials used in the method do not comprise hydroxyapatite, and wherein the VLPs are
purified to greater than about 70%.
US Pat. No. 9,867,876

PARENTERAL NOROVIRUS VACCINE FORMULATIONS

Takeda Vaccines, Inc., C...

1. A composition comprising a genogroup I Norovirus virus-like particle (VLP) and a genogroup II Norovirus VLP, wherein the
genogroup I and genogroup II Norovirus VLPs are present in the composition in different amounts, and wherein the genogroup
I Norovirus VLP is present in the composition at an amount of about 15 ?g and the genogroup II Norovirus VLP is present in
the composition at an amount of about 50 ?g.
US Pat. No. 10,010,599

NOROVIRUS VACCINE FORMULATIONS

TAKEDA VACCINES, INC., C...

1. A method of generating an immune response to at least two Norovirus strains by administering to a patient an antigenic formulation comprising a combination of two or more monovalent Norovirus VLPs of different Norovirus genotypes, or an antigenic formulation comprising multivalent VLPs containing capsid proteins from two or more different Norovirus genotypes, wherein at least one of the two or more Norovirus genotypes is a genogroup I genotype I.1 and at least one of the two or more Norovirus genotypes is a genogroup II genotype II.4, such that the combination of VLPs within the formulation does not block the immunogenicity of each VLP type, and wherein immunity is generated against at least one Norovirus strain having a genotype that is different than the genotypes of said VLPs in said formulation.
US Pat. No. 9,878,031

COMPOSITIONS, METHODS OF ADMINISTRATION AND USES FOR TRIVALENT DENGUE VIRUS FORMULATIONS

Takeda Vaccines, Inc., C...

1. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;
administering a first dose of a single trivalent dengue virus immunogenic composition comprising a mixture of three or more
different live, attenuated dengue viruses, wherein the mixture comprises at least three dengue virus serotypes comprising
dengue-dengue chimeras, wherein the dengue-dengue chimeras comprise dengue virus structural proteins on an attenuated dengue-2
virus backbone, and one or more structural elements of dengue-1, dengue-2, dengue-3 or dengue-4, and one or more structural
or non-structural elements of a live, attenuated dengue virus, and wherein the attenuated dengue-2 virus comprises dengue-2
strain PDK-53, and wherein three of four dengue virus serotype structural elements are present in the single trivalent dengue
virus immunogenic composition; and

administering at least a second dose of a live, attenuated dengue virus immunogenic composition comprising a single live,
attenuated dengue virus chimera or a monovalent live, attenuated dengue virus on the same day or up to 180 days after administration
of the first dose of the single trivalent dengue virus immunogenic composition.

US Pat. No. 9,211,323

COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS

TAKEDA VACCINES, INC., D...

1. A method for inducing an immune response in a subject against three or more dengue virus serotypes, comprising,
administering to the subject by at least a first intradermal introduction, a first immunogenic composition of a mixture of
three or more live, attenuated dengue viruses, the composition comprising at least one dengue-dengue chimera and three or
more different dengue virus serotype in the mixture, and administering at least a second intradermal introduction(s) of a
second immunogenic composition against one or more dengue virus serotypes within 30 days after the first administration of
the first immunogenic composition to the subject and inducing an immune response in the subject against three or more dengue
virus serotypes.

US Pat. No. 9,821,049

METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS

Takeda Vaccines, Inc., C...

1. A method of eliciting protective immunity against Norovirus in a human comprising the steps of:
(i) intramuscularly administering to the human a vaccine comprising Norovirus virus-like particles (VLPs), wherein the Norovirus
VLPs are present in the vaccine in an amount of 1 ?g to 200 ?g, wherein the vaccine comprises at least one adjuvant that is
not a bacterially-derived exotoxin adjuvant, and wherein the administration of the vaccine elicits production of Norovirus-specific
functional antibodies in a blood sample from the human; and

(ii) measuring the Norovirus-specific functional antibodies in the blood sample from the human, wherein a geometric mean serum
titer of the Norovirus-specific functional antibodies greater than 40 as measured by a carbohydrate blocking assay is indicative
of protective immunity.

US Pat. No. 10,449,231

COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES

TAKEDA VACCINES, INC., C...

1. A nucleic acid sequence comprising a nucleic acid sequence encoding a modified live, attenuated dengue-2 virus represented by SEQ ID NO:13 (WVS).
US Pat. No. 10,052,374

COMPOSITIONS, METHODS AND USES FOR DENGUE VIRUS SEROTYPE-4 CONSTRUCTS

Takeda Vaccines, Inc., C...

1. A tetravalent dengue virus composition comprising:live, attenuated dengue viruses comprising a dengue-2/4 chimera, wherein the dengue-2/4 chimera comprises a live, attenuated dengue-2 virus backbone having one or more structural proteins from a dengue-4 virus, and wherein a nucleic acid construct encoding the live, attenuated dengue-2/4 chimera further comprises one or more mutations, the one or more mutations comprising:
a mutation in an envelope (E) protein at an amino acid position synonymous to amino acid 417 of dengue-4 when the E protein is from dengue-4, wherein the mutation in the E protein at the position synonymous to amino acid 417 changes glutamic acid to a positively charged amino acid residue;
a mutation in the capsid (C) protein at an amino acid position synonymous to amino acid 107 in the live, attenuated dengue-2 virus backbone, wherein the mutation in the C protein at the position synonymous to amino acid 107 changes cysteine to an aromatic amino acid residue in dengue-2 virus backbone; and
a mutation in nonstructural protein 4A (NS4A) at an amino acid position synonymous to amino acid 17 in the dengue-2 virus backbone; and
one or more live, attenuated flaviviruses or one or more flavivirus chimeras, wherein the composition comprises all four dengue virus serotypes, dengue-1, dengue-2, dengue-3 and dengue-4, wherein the dengue-4 virus is present in the composition in an amount that is at least one log greater than the amount of dengue-2 virus.
US Pat. No. 9,861,691

NOROVIRUS VACCINE FORMULATIONS

Takeda Vaccines, Inc., C...

1. A composition comprising two or more Norovirus antigens and a mucoadhesive, wherein at least one of the Norovirus antigens
is from genogroup I and at least one of the Norovirus antigens is from genogroup II, and wherein the amount of each of the
two or more Norovirus antigens is from about 1 ?g to about 100 ?g per dose.
US Pat. No. 10,010,600

COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS

TAKEDA VACCINES, INC., C...

1. A method for inducing an immune response in a subject against all four dengue virus serotypes, comprising,administering to the subject by at least a first introduction, an immunogenic composition of a mixture comprising components of all four dengue virus serotypes, the composition comprising at least one live, attenuated dengue chimera comprising dengue-2/1, dengue-2/3 and dengue-2/4; and at least a non-chimera live, attenuated dengue-2 virus, and administering at least a second introduction of the immunogenic composition within 30 days of but not on the same day as, the first introduction to the subject and inducing an immune response in the subject against all four dengue virus serotypes.
US Pat. No. 10,130,696

METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS

TAKEDA VACCINES, INC., C...

1. A method of eliciting protective immunity to a Norovirus infection in a human comprising administering to the human a vaccine comprising at least one Norovirus virus-like particle (VLP) wherein the content of each Norovirus VLP in the vaccine is from about 1 ?g to about 50 ?g.
US Pat. No. 9,834,757

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF

Takeda Vaccines, Inc., C...

5. A hand, foot, and mouth immunogenic composition comprising at least one intact, inactivated virus that causes hand, foot
and mouth disease in humans and a detergent in an effective concentration, wherein:
a. the at least one intact, inactivated virus was inactivated with BEI;
b. the composition does not comprise an adjuvant, or comprises an aluminum salt adjuvant; or
c. (a) and (b).
US Pat. No. 10,167,320

PURIFICATION OF VIRUS LIKE PARTICLES

Takeda Vaccines, Inc., C...

1. A solution comprising a purified population of human norovirus VLPs, wherein the norovirus VLPs comprise at least genogroup II VLPs, wherein said solution contains no more than about 80% residual contaminating protein relative to VLP, and wherein said solution is generated by a process comprising:generating or obtaining a cell lysate, culture supernatant, or filtrate containing the norovirus VLPs, wherein said norovirus VLPs comprise at least a first subpopulation with full length VP1 subunit and a second subpopulation with truncated VP1 subunit of the norovirus VLPs;
adjusting the pH of the lysate, supernatant or filtrate to a pH of less than about 5 to generate a pH-adjusted solution;
removing the second subpopulation with truncated VP1 subunit of norovirus VLPs from the pH-adjusted solution using a filtration process to generate a filtered solution, wherein the filtered solution substantially retains the first subpopulation with full length VP1 subunit of norovirus VLPs;
and
wherein the solution comprises full length VP1 subunit of norovirus VLPs and is substantially free of norovirus VLPs with the truncated VP1 subunit, wherein the solution contains less than about 10% truncated VP1 subunit.

US Pat. No. 10,137,186

COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS

Takeda Vaccines, Inc., C...

1. A live, attenuated alphavirus virus composition comprising:one or more live, attenuated alphaviruses, wherein the live, attenuated alphaviruses are selected from the group consisting of chikungunya (CHIK) virus, o'nyong'nyong virus, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis;
10.0 mM to 20.0 mM HEPES buffer;
one or more carbohydrate agents having a concentration from 1.0% to 15% (w/v) selected from the group consisting of: trehalose, sucrose, mannitol, sorbitol, and galactose; and
0.1% to 1.0% (w/v) gelatin but does not contain human serum albumin (HSA), wherein the composition stabilizes the live attenuated alphaviruses.
US Pat. No. 10,233,429

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF

Takeda Vaccines, Inc., C...

1. A hand, foot, and mouth immunogenic composition comprising at least one intact, inactivated virus that causes hand, foot and mouth disease in humans and a detergent in an effective concentration.
US Pat. No. 9,890,362

COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH

Takeda Vaccines, Inc., C...

1. A method for culturing viruses for production and manufacture, the method comprising:
growing host cells;
introducing to the host cells a composition comprising media for growing viral cultures comprising one or more ethylene oxide
propylene oxide (EO-PO) block copolymers before, during, or after viral infection of the host cells; the one or more EO-PO
block copolymers comprising poloxamer 407, poloxamer 403, or a combination thereof, wherein the concentration of the EO-PO
block copolymer is from 0.001% to 3.0% (w/v);

introducing viruses to the host cells before, during or after introduction of the composition;
incubating the host cells, the viruses, and the media for a predetermined period to culture the viruses;
separating the media from the host cells; and
harvesting the cultured viruses from the media.
US Pat. No. 9,713,638

COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS

Takeda Vaccines, Inc., D...

1. A method for inducing an immune response in a subject against three or more dengue virus serotypes, the method comprising:
administering a first immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising
at least one non-chimeric live, attenuated dengue-2 virus and at least one dengue-dengue chimera having a live, attenuated
dengue-2 virus backbone; and

administering a second immunogenic composition of three or more live, attenuated dengue viruses, the composition comprising
at least one of a non-chimeric live, attenuated dengue-2 virus and a dengue-dengue chimera having a live, attenuated dengue-2
virus backbone;

wherein the first immunogenic composition and the second immunogenic composition are administered subcutaneously at two or
more anatomical locations consecutively on the same day to the subject; and

inducing an immune response in the subject against the three or more dengue virus serotypes.
US Pat. No. 10,172,930

VIRUS LIKE PARTICLE PURIFICATION

TAKEDA VACCINES, INC., C...

1. A composition comprising Norovirus genogroup II, genotype 4 (GII.4) virus-like particles (VLPs), wherein the composition is prepared by a method comprising contacting a solution containing said VLPs with at least one chromatographic material, wherein the at least one chromatographic material is an anion exchange chromatographic material, wherein the chromatographic materials used in the method do not comprise hydroxyapatite, and wherein the VLPs are present in the composition at a purity level of greater than about 90%.
US Pat. No. 10,675,341

PARENTERAL NOROVIRUS VACCINE FORMULATIONS

Takeda Vaccines, Inc., C...

1. A method of eliciting protective immunity against Norovirus in a human comprising administering parenterally to the human no more than a single dose of a vaccine composition, said composition comprising(i) genogroup I Norovirus virus-like particles (VLPs), wherein said genogroup I Norovirus VLPs comprise a capsid protein derived from a genogroup I viral strain, and
(ii) genogroup II Norovirus VLPs, wherein said genogroup II Norovirus VLPs comprise a capsid protein derived from a genogroup II viral strain,
wherein said genogroup I Norovirus VLPs and genogroup II Norovirus VLPs are present in the composition in different amounts, wherein said composition comprises about 15 ?g to 50 ?g of genogroup I Norovirus VLPs and about 50 ?g to 150 ?g of genogroup II Norovirus VLPs,
wherein said composition induces at least a three-fold increase in Norovirus-specific serum antibody titer as compared to the titer in the human prior to administration of the composition.
US Pat. No. 10,688,174

METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS

Takeda Vaccines, Inc., C...

1. A method of eliciting protective immunity to a Norovirus infection in a human comprising administering to the human a vaccine comprising at least two Norovirus virus-like particles (VLPs), wherein the at least two VLPs represent different Norovirus genotypes, wherein at least one Norovirus VLP is present in the vaccine in a dose amount of from about 1 ug to about 200 ug, and wherein the vaccine is able to elicit immunity against each Norovirus genotype represented in the vaccine.
US Pat. No. 10,501,500

METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES

Takeda Vaccines, Inc., C...

1. A method for detecting a virus comprising detecting a nucleic acid sequence comprising at least 50 contiguous nucleotides of SEQ ID NO: 1 or the reverse complement sequence of SEQ ID NO: 1.
US Pat. No. 10,632,184

COMPOSITIONS AND METHODS FOR STABILIZING ALPHAVIRUSES WITH IMPROVED FORMULATIONS

TAKEDA VACCINES, INC., C...

1. A live attenuated alphavirus composition comprising:one or more live alphaviruses;
one or more amino acids that include histidine;
two or more carbohydrate agents; andwherein the composition does not include serum or gelatin and wherein the composition stabilizes live alphaviruses.
US Pat. No. 10,525,120

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES

TAKEDA VACCINES, INC., C...

1. A virus composition comprising:one or more live, attenuated flaviviruses; and a stabilizing composition comprising serum albumin and trehalose,
wherein the one or more live, attenuated flaviviruses consists of one or more Dengue viruses;
wherein the serum albumin is serum albumin from a vertebrate species, and is present at a concentration of 0.001 to 3.0% (w/v);
wherein the trehalose is present at a concentration of at least 15% (w/v); and
wherein the composition is capable of reducing the inactivation of the one or more live, attenuated Dengue viruses.
US Pat. No. 10,512,682

NOROVIRUS VACCINE FORMULATIONS

Takeda Vaccines, Inc., C...

1. A method of generating an immune response to at least two Norovirus strains by administering to a patient an antigenic formulation comprising a combination of two or more monovalent Norovirus VLPs of different Norovirus genotypes, or an antigenic formulation comprising multivalent VLPs containing capsid proteins from two or more different Norovirus genotypes, such that the combination of VLPs within the formulation does not block the immunogenicity of each VLP type.
US Pat. No. 10,920,288

DETECTION OF PARTICLE-CONTAINED REVERSE TRANSCRIPTASE ACTIVITY

Takeda Vaccines, Inc., C...

1. A method for detecting the presence of virus particle-contained reverse transcriptase activity in a test sample comprising steps of:(1) adding to the test sample a protease and a detergent in an amount that is insufficient to disrupt an intact virus particle and incubating the resultant solution under conditions that allow the protease to digest any soluble reverse transcriptase present in the resultant solution, thereby producing a digested solution;
(2) inactivating the protease in the digested solution, thereby producing an inactivated protease solution;
(3) adding a detergent in an amount that is sufficient to disrupt an intact virus particle, thereby producing a detergent-containing solution;
(4) adding into the detergent-containing solution or into a fraction of the detergent-containing solution (i) an isolated RNA molecule, (ii) a first primer that hybridizes to a nucleic acid sequence corresponding to a first part of the isolated RNA molecule, (iii) a second primer that hybridizes to the complement of a second part of the isolated RNA molecule, and (iv) a DNA polymerase, thereby preparing a PCR-based reverse transcriptase (PBRT) assay solution;
(5) incubating the PBRT assay solution under conditions that allow a reverse transcription product to be synthesized from the isolated RNA molecule and a PCR-amplified product from the reverse transcription product if a virus particle-contained reverse transcriptase is present in the test sample; and
(6) identifying the PCR-amplified product, thereby detecting the presence of the virus particle-contained reverse transcriptase in the test sample.

US Pat. No. 10,806,781

COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS

Takeda Vaccines, Inc., C...

1. A live attenuated alphavirus virus composition comprising:one or more live, attenuated alphaviruses selected from the group consisting of chikungunya (CHIK) virus, o'nyong'nyong virus, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis;
10.0 to 20.0 mM HEPES buffer;
one or more carbohydrate agents having a concentration from 1.0% to 15% (w/v) selected from the group consisting of: trehalose, sucrose, mannitol, sorbitol, and galactose; and
0.1% to 1.0% (w/v) gelatin,wherein the composition stabilizes live attenuated alphavirus compositions.
US Pat. No. 10,792,353

VIRUS LIKE PARTICLE PURIFICATION

Takeda Vaccines, Inc., C...

1. A production method for Norovirus virus-like particles (VLPs), comprising:transforming insect cells with a baculovirus vector containing a viral nucleic acid sequence encoding a Norovirus major capsid protein VP1;
cultivating the insect cells in a medium thereby expressing the VLPs in the medium;
stopping cultivation when the viability of the insect cells reaches 20% or less; and
isolating supernatant comprising the VLPs from the insect cells thus producing the VLPs.
US Pat. No. 10,898,565

COMPOSITIONS, METHODS AND USES FOR DENGUE VIRUS SEROTYPE-4 CONSTRUCTS

Takeda Vaccines, Inc., C...

1. A tetravalent dengue virus composition comprising:live, attenuated dengue viruses comprising a dengue-2/4 chimera, wherein the dengue-2/4 chimera comprises a live, attenuated dengue-2 virus backbone having one or more structural proteins from a dengue-4 virus, and wherein a nucleic acid construct encoding the live, attenuated dengue-2/4 chimera further comprises one or more mutations, the one or more mutations comprising:
a mutation in an envelope (E) protein at an amino acid position synonymous to amino acid 417 of dengue-4 when the E protein is from dengue-4, wherein the mutation in the E protein at the position synonymous to amino acid 417 changes glutamic acid to a positively charged amino acid residue;
a mutation in the capsid (C) protein at an amino acid position synonymous to amino acid 107 in the live, attenuated dengue-2 virus backbone, wherein the mutation in the C protein at the position synonymous to amino acid 107 changes cysteine to an aromatic amino acid residue in dengue-2 virus backbone; and
a mutation in nonstructural protein 4A (NS4A) at an amino acid position synonymous to amino acid 17 in the dengue-2 virus backbone; and
one or more live, attenuated flaviviruses or one or more flavivirus chimeras, wherein the composition comprises all four dengue virus serotypes, dengue-1, dengue-2, dengue-3 and dengue-4.
US Pat. No. 10,835,597

COMPOSITIONS AND METHODS FOR STABILIZING FLAVIVIRUSES WITH IMPROVED FORMULATIONS

TAKEDA VACCINES, INC., C...

1. A flavivirus composition comprising:one or more live flaviviruses;
at least one of trehalose in a concentration ranging from 5.0% to 15.0% (w/v) and sucrose in a concentration ranging from 5.0% to 15.0% (w/v);
urea;
mannitol; and
human serum albumin.
US Pat. No. 10,806,782

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF

Takeda Vaccines, Inc., D...

1. A hand, foot, and mouth immunogenic composition comprising one or more antigens from a chemically-inactivated enterovirus 71 (EV71), wherein the one or more antigens comprise the VP1 polypeptide of EV71, wherein the VP1 polypeptide comprises four mutations comprising:(i) a valine to methionine substitution at position 7 of SEQ ID NO: 1, or at a position corresponding to position 7 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1 using a pairwise alignment algorithm;
(ii) an aspartic acid to asparagine substitution at position 14 of SEQ ID NO: 1, or at a position corresponding to position 14 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1 using a pairwise alignment algorithm;
(iii) a glutamic acid to glutamine substitution at position 145 of SEQ ID NO: 1, or at a position corresponding to position 145 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1 using a pairwise alignment algorithm; and
(iv) an asparagine to aspartic acid substitution at a position corresponding to position 282 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1 using a pairwise alignment algorithm.